A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

[1]  B. Ferrell,et al.  An evaluation of the quality of life among long-term survivors of breast cancer , 2005, Breast Cancer Research and Treatment.

[2]  R. Epstein,et al.  Interpretation of quality of life changes , 1993, Quality of Life Research.

[3]  M. King,et al.  Quality of life three months and one year after first treatment for early stage breast cancer: Influence of treatment and patient characteristics , 2004, Quality of Life Research.

[4]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[5]  P. Ganz,et al.  Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock. , 2003, Journal of the National Cancer Institute.

[6]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Fleming.  Locally Advanced, Locally Recurrent, and Metastatic Breast Cancer , 2003 .

[8]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[9]  D. Osoba,et al.  Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Patrick,et al.  Assessing meaningful change in quality of life over time: a users' guide for clinicians. , 2002, Mayo Clinic proceedings.

[11]  T. Rummans,et al.  The clinical significance of quality-of-life results: practical considerations for specific audiences. , 2002, Mayo Clinic proceedings.

[12]  R. Hays,et al.  Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores , 2002 .

[13]  S. Hirschfeld,et al.  Oncology drug development: United States Food and Drug Administration perspective. , 2002, Critical reviews in oncology/hematology.

[14]  D. Northfelt,et al.  Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. , 2002, Journal of pain and symptom management.

[15]  J. Sloan,et al.  Assessing the clinical significance of single items relative to summated scores. , 2002, Mayo Clinic proceedings.

[16]  D. Cella,et al.  Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. , 2002, Mayo Clinic proceedings.

[17]  Tara Symonds,et al.  Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. , 2002, Mayo Clinic proceedings.

[18]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[19]  D. Cella,et al.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. , 2002, Journal of clinical epidemiology.

[20]  E. Winer,et al.  Primary care for survivors of breast cancer. , 2000, The New England journal of medicine.

[21]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Tierney,et al.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.

[23]  P. Ganz,et al.  Quality of life of African‐American and white long term breast carcinoma survivors , 1999, Cancer.

[24]  N. Polissar,et al.  Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Tate,et al.  Quality of life issues among women with physical disabilities or breast cancer. , 1997, Archives of physical medicine and rehabilitation.

[27]  D S Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Salovey,et al.  Psychosocial sequelae of breast cancer and its treatment , 1996, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[30]  Thomas J. Smith,et al.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. , 1995, Lung cancer.

[32]  Katherine R. Edwards,et al.  When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function , 1995, Pain.

[33]  C. Saunders.  Current management of breast cancer. , 1993, British journal of hospital medicine.

[34]  D. Tulsky,et al.  Quality of life in cancer: definition, purpose, and method of measurement. , 1993, Cancer investigation.

[35]  D. Cella,et al.  Quality-of-life assessment in cancer clinical trials: a status report. , 1992, Journal of the National Cancer Institute.

[36]  Karen Glanz,et al.  Psychosocial Impact of Breast Cancer: A Critical Review , 1992, Annals of Behavioral Medicine.

[37]  P. Ganz,et al.  Assessing the quality of life--a study in newly-diagnosed breast cancer patients. , 1990, Journal of clinical epidemiology.

[38]  C. Chapman,et al.  Issues in pain measurement , 1989 .

[39]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[40]  R. Temple,et al.  Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.

[41]  B. Meyerowitz.  Psychosocial correlates of breast cancer and its treatments. , 1980, Psychological bulletin.

[42]  Emil Frei,et al.  Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .